Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:49 UTC |
---|
HMDB ID | HMDB0014989 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Dacarbazine |
---|
Description | Dacarbazine is only found in individuals that have used or taken this drug. It is an antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific. |
---|
Structure | CN(C)N=NC1=C(N=CN1)C(N)=O InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9) |
---|
Synonyms | Value | Source |
---|
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide | ChEBI | 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide | ChEBI | 4-(Dimethyltriazeno)imidazole-5-carboxamide | ChEBI | 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide | ChEBI | 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide | ChEBI | 5-(Dimethyltriazeno)imidazole-4-carboxamide | ChEBI | Dacarbazina | ChEBI | Dacarbazinum | ChEBI | Deticene | ChEBI | Di-me-triazenoimidazolecarboxamide | ChEBI | DIC | ChEBI | DTIC | ChEBI | Dtic-dome | ChEBI | HSDB 3219 | ChEBI | ICDMT | ChEBI | NCI-C04717 | ChEBI | NSC 45388 | ChEBI | NSC-45388 | ChEBI | DTCI | HMDB | Biocarbazine R | HMDB | DTIE | HMDB | ICDT | HMDB | Imidazole carboxamide | HMDB | Biocarbazine | MeSH | Carboxamide, dimethyl imidazole | MeSH | DTIC dome | MeSH | DTICDome | MeSH | Decarbazine | MeSH | Dimethyl imidazole carboxamide | MeSH | Dimethyl triazeno imidazole carboxamide | MeSH | Imidazole carboxamide, dimethyl | MeSH |
|
---|
Chemical Formula | C6H10N6O |
---|
Average Molecular Weight | 182.1832 |
---|
Monoisotopic Molecular Weight | 182.091608972 |
---|
IUPAC Name | 5-(dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide |
---|
Traditional Name | dacarbazine - dtic |
---|
CAS Registry Number | 4342-03-4 |
---|
SMILES | CN(C)N=NC1=C(N=CN1)C(N)=O |
---|
InChI Identifier | InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9) |
---|
InChI Key | FDKXTQMXEQVLRF-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 2-heteroaryl carboxamides. 2-Heteroaryl carboxamides are compounds containing a heteroaromatic ring that carries a carboxamide group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Carboxylic acid derivatives |
---|
Direct Parent | 2-heteroaryl carboxamides |
---|
Alternative Parents | |
---|
Substituents | - 2-heteroaryl carboxamide
- Imidazole-4-carbonyl group
- Azole
- Imidazole
- Heteroaromatic compound
- Vinylogous amide
- Primary carboxylic acid amide
- Propargyl-type 1,3-dipolar organic compound
- Azacycle
- Organoheterocyclic compound
- Organic 1,3-dipolar compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 205 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 1.36 g/L | Not Available | LogP | -1.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dacarbazine,1TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=C[NH]1 | 1779.6 | Semi standard non polar | 33892256 | Dacarbazine,1TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=C[NH]1 | 1934.9 | Standard non polar | 33892256 | Dacarbazine,1TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=C[NH]1 | 3731.2 | Standard polar | 33892256 | Dacarbazine,1TMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C | 1913.9 | Semi standard non polar | 33892256 | Dacarbazine,1TMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C | 1956.1 | Standard non polar | 33892256 | Dacarbazine,1TMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C | 3542.3 | Standard polar | 33892256 | Dacarbazine,2TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=CN1[Si](C)(C)C | 1853.0 | Semi standard non polar | 33892256 | Dacarbazine,2TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=CN1[Si](C)(C)C | 2052.2 | Standard non polar | 33892256 | Dacarbazine,2TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C)N=CN1[Si](C)(C)C | 3316.3 | Standard polar | 33892256 | Dacarbazine,2TMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=C[NH]1 | 1816.3 | Semi standard non polar | 33892256 | Dacarbazine,2TMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=C[NH]1 | 2063.8 | Standard non polar | 33892256 | Dacarbazine,2TMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=C[NH]1 | 3442.8 | Standard polar | 33892256 | Dacarbazine,3TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=CN1[Si](C)(C)C | 1955.2 | Semi standard non polar | 33892256 | Dacarbazine,3TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=CN1[Si](C)(C)C | 2117.8 | Standard non polar | 33892256 | Dacarbazine,3TMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C)[Si](C)(C)C)N=CN1[Si](C)(C)C | 2997.6 | Standard polar | 33892256 | Dacarbazine,1TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=C[NH]1 | 1987.2 | Semi standard non polar | 33892256 | Dacarbazine,1TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=C[NH]1 | 2094.8 | Standard non polar | 33892256 | Dacarbazine,1TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=C[NH]1 | 3732.5 | Standard polar | 33892256 | Dacarbazine,1TBDMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C(C)(C)C | 2088.2 | Semi standard non polar | 33892256 | Dacarbazine,1TBDMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C(C)(C)C | 2145.1 | Standard non polar | 33892256 | Dacarbazine,1TBDMS,isomer #2 | CN(C)N=NC1=C(C(N)=O)N=CN1[Si](C)(C)C(C)(C)C | 3587.4 | Standard polar | 33892256 | Dacarbazine,2TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 2234.3 | Semi standard non polar | 33892256 | Dacarbazine,2TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 2372.5 | Standard non polar | 33892256 | Dacarbazine,2TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 3344.4 | Standard polar | 33892256 | Dacarbazine,2TBDMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C[NH]1 | 2195.5 | Semi standard non polar | 33892256 | Dacarbazine,2TBDMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C[NH]1 | 2429.5 | Standard non polar | 33892256 | Dacarbazine,2TBDMS,isomer #2 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C[NH]1 | 3442.3 | Standard polar | 33892256 | Dacarbazine,3TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 2492.3 | Semi standard non polar | 33892256 | Dacarbazine,3TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 2657.8 | Standard non polar | 33892256 | Dacarbazine,3TBDMS,isomer #1 | CN(C)N=NC1=C(C(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN1[Si](C)(C)C(C)(C)C | 3058.3 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Dacarbazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-002f-7900000000-1b20185f2f8cede43985 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dacarbazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 10V, Positive-QTOF | splash10-001i-0900000000-19e145e04a29e85dbb78 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 20V, Positive-QTOF | splash10-0159-0900000000-46878b8c1d5ef1a88f40 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 40V, Positive-QTOF | splash10-0006-6900000000-7776976c8e2de261cdae | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 10V, Negative-QTOF | splash10-001i-1900000000-454c00afd7e71a2e94de | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 20V, Negative-QTOF | splash10-001c-2900000000-1247d4cc570997f56811 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 40V, Negative-QTOF | splash10-0006-9400000000-3bc8cd08fb9775dce145 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 10V, Positive-QTOF | splash10-00lr-0900000000-06f8b85fb44ca1de41ad | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 20V, Positive-QTOF | splash10-001v-5900000000-bb28672b3383c5c86fda | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 40V, Positive-QTOF | splash10-052b-9100000000-43b8467f20b35711585f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 10V, Negative-QTOF | splash10-000x-7900000000-45eda8c3304bd65c690f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 20V, Negative-QTOF | splash10-0006-9000000000-d22f5484d8086a357256 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dacarbazine 40V, Negative-QTOF | splash10-0006-9000000000-5a148f839c246fca824b | 2021-10-11 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00851 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00851 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 10437816 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Dacarbazine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 2942 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 4305 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Psaroudi MC, Kyrtopoulos SA: Toxicity, mutation frequency and mutation spectrum induced by dacarbazine in CHO cells expressing different levels of O(6)-methylguanine-DNA methyltransferase. Mutat Res. 2000 Feb 14;447(2):257-65. [PubMed:10751609 ]
- Safgren SL, Reid JM, Rios R, Ames MM: Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):91-6. [PubMed:11318431 ]
- Sanada M, Takagi Y, Ito R, Sekiguchi M: Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair (Amst). 2004 Apr 1;3(4):413-20. [PubMed:15010317 ]
- Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16. [PubMed:20082117 ]
- Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, Park KW, Lee J: Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011 Jun;21(3):223-7. doi: 10.1097/CMR.0b013e3283457743. [PubMed:21471822 ]
- Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prevost-Blondel A: Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol. 2011 Sep;131(9):1896-905. doi: 10.1038/jid.2011.128. Epub 2011 Jun 9. [PubMed:21654834 ]
- Engesaeter B, Engebraaten O, Florenes VA, Maelandsmo GM: Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492. doi: 10.1371/journal.pone.0045492. Epub 2012 Sep 20. [PubMed:23029050 ]
|
---|